全基因组、转录组和甲基化组分析促进高危儿童癌症可操作靶点发现
Zero Childhood Cancer Program 对252例高危儿童肿瘤进行WGS和RNAseq,识别968个可报告分子异常,93.7%患者有至少一个胚系或体细胞异常,71.4%有治疗靶点,5.2%诊断改变。43例接受推荐治疗,38例可评估,31%显示客观临床获益。
要点
- WGS和RNAseq联合可提高可报告分子异常检出率。
- 高危儿童肿瘤中71.4%存在治疗靶点,5.2%诊断改变。
- 接受推荐治疗的可评估患者中31%有客观临床获益。
核心结论
- 全面分子谱分析可解析几乎所有高危儿童癌症的分子基础,并为部分患者带来临床获益。
研究设计与样本
- Zero Childhood Cancer Program 精准医学项目,对252例高危儿童肿瘤患者进行肿瘤和胚系WGS及RNAseq。
主要发现
- 共识别968个可报告分子异常,39.9%来自WGS和RNAseq,35.1%仅WGS,25.0%仅RNAseq。
- 93.7%患者有至少一个胚系或体细胞异常,71.4%有治疗靶点,5.2%诊断改变。
- WGS在16.2%患者中识别致病性癌症易感变异。
- 76例中枢神经系统肿瘤中,甲基化分析确认诊断71.1%,2例(2.6%)诊断改变。
- 43例接受推荐治疗,38例可评估,31%显示客观临床获益证据。
临床怎么用
- 对高危、罕见、复发或难治性儿童癌症可考虑WGS联合RNAseq及甲基化分析以发现可操作靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Zero Childhood Cancer Program is a precision medicine program to benefit children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline whole genome sequencing (WGS) and RNA sequencing (RNAseq) across 252 tumors from high-risk pediatric patients with cancer, we identified 968 reportable molecular aberrations (39.9% in WGS and RNAseq, 35.1% in WGS only and 25.0% in RNAseq only). Of these patients, 93.7% had at least one germline or somatic aberration, 71.4% had therapeutic targets and 5.2% had a change in diagnosis. WGS identified pathogenic cancer-predisposing variants in 16.2% of patients. In 76 central nervous system tumors, methylome analysis confirmed diagnosis in 71.1% of patients and contributed to a change of diagnosis in two patients (2.6%). To date, 43 patients have received a recommended therapy, 38 of whom could be evaluated, with 31% showing objective evidence of clinical benefit. Comprehensive molecular profiling resolved the molecular basis of virtually all high-risk cancers, leading to clinical benefit in some patients.
引用
- Wong M, Mayoh C, Lau LMS, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020. PMID: 33020650. doi:10.1038/s41591-020-1072-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。